Sun gets NJ plant back on GMP track, still working on Detroit facility

Sun Pharmaceutical Industries is back on track with the FDA regarding its Cranbury, NJ, manufacturing plant. Results of a June re-inspection found the plant had "an acceptable regulatory status."   

The re-inspection follows an Aug. 25, 2010, warning letter that included GMP violations for its inability to produce drug batches of consistent quality and for a lack of detail in the fixes it was proposing to the FDA. 

Sun is not out of the regulatory woods yet, however. In Detroit, Sun subsidiary Caraco continues to work with consultants to resolve the manufacturing shortcomings. It's been operating under a consent decree with the FDA since 2009. GMP violations eventually led to seizure of 33 medications by U.S. Marshals and the subsequent shutdown of plants in plants in Detroit, Farmington Hills and Wixom, MI.

- see the story
- read the Marketwatch coverage
- and here's more

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.